Few sectors attract as much excitement, scepticism and confusion as life sciences.
One headline about a breakthrough can send valuations soaring. One trial setback can wipe billions from a company overnight. Investors swing between euphoria and doubt, often treating scientific progress as if it should move to the rhythm of quarterly earnings reports.
I’ve long believed that this is where many markets go wrong.
The problem is not life sciences. The problem is the lens through which life sciences is judged.
Science does not unfold in straight lines. It does not care about reporting seasons or short-term sentiment. It advances through experimentation, iteration, failure, learning and persistence. When investors apply the logic of consumer markets or software growth curves to biology, they often misunderstand where real value is being created.
That matters, because some of the most important opportunities of our time sit in this space.
Drug development is not slow because the system is broken. It is slow because the stakes are high.
Before a therapy reaches patients, it must pass through years of research, testing and scrutiny. Ideas that look promising in the laboratory often fail in human trials. Positive early data must be challenged, replicated and validated at scale. Regulators then apply another necessary layer of examination.
This can appear frustrating to markets that prize speed. But in medicine, caution is not inefficiency. It is responsibility.
Setbacks are not always signs that something has gone wrong. Often, they are evidence that the process is working exactly as it should.
That is why patience is not optional in life sciences. It is part of the investment discipline.
When capital expects immediate certainty, it becomes poorly matched to the reality of scientific development. When capital understands the journey, it can help build enduring value.
One of the biggest mistakes in the sector is to think only in terms of single products.
Of course individual therapies matter. They can transform lives and redefine categories of care. But increasingly, the more interesting opportunity lies beneath the product itself.
You are not only investing in one drug candidate. You may be investing in a platform that can produce many therapies. You may be investing in data systems that improve how diseases are understood. You may be investing in tools that make research faster, more precise and more scalable.
That distinction changes everything.
A single molecule may succeed or fail. A strong scientific platform can generate multiple shots on goal over time. It can learn, improve and create value beyond any one programme.
This is one reason I’ve been drawn to areas such as AI-enabled drug discovery, research infrastructure and businesses working on the biology of ageing. These are not quick trades. They are long-duration bets on capability.
And capability compounds.
Another reason life sciences deserves a different framework is that its demand drivers are fundamentally different from many other sectors.
Healthcare demand is not based on fashion or consumer whim. It is anchored in human need.
Populations are ageing. Chronic disease is rising. Healthcare systems are under strain. In many countries, the cost of inaction is becoming unsustainable.
That means innovation in oncology, immunology, rare disease, diagnostics and preventative medicine is not a luxury. It is essential infrastructure for the future.
When capital flows into these areas, it is not merely chasing the next trend. It is responding to structural realities that are likely to intensify over time.
Markets sometimes treat healthcare innovation as a niche theme. I see it differently. It is one of the defining economic and social priorities of the decades ahead.
The structure of capital matters as much as the amount of it.
Public markets can be powerful engines of growth, but they often struggle with scientific uncertainty. Share prices react instantly to partial data, delays or shifting timelines. That can create volatility disconnected from the underlying quality of the science.
Private capital can sometimes be better aligned.
With the right governance and expertise, long-term investors can fund programmes through periods where progress is real but not yet obvious to the market. They can support management teams through complexity rather than demanding premature simplification. They can measure progress against scientific milestones, not just calendar quarters.
This is not about public versus private as ideology. Both have an important role. It is about fit.
Some forms of capital are simply better suited to long development cycles than others.
From the outside, life sciences can look chaotic.
Trials fail. Regulators ask hard questions. Timelines shift. Markets overreact.
But volatility should not automatically be confused with fragility.
Scientific discovery has always involved uncertainty. That is the price of learning something genuinely new. Over time, progress is cumulative. Knowledge builds. Tools improve. Failure today often becomes the foundation of success tomorrow.
We are already seeing this in areas such as genomics, machine learning, regenerative medicine and precision diagnostics. These are not isolated breakthroughs. They are part of a broader reimagining of how healthcare is delivered.
The market may focus on today’s noise. But the deeper story is one of expanding possibility.
In a world obsessed with speed, life sciences asks something different of investors.
It asks for patience. It asks for conviction. It asks for the ability to distinguish temporary uncertainty from long-term value creation.
That can be uncomfortable. But discomfort is not always a warning sign. Sometimes it is the price of entering fields where the greatest progress is still being built.
I do not see life sciences as inherently speculative or unknowable. I see it as a sector measured on a different clock.
And those who understand that are often better placed to recognise value before everyone else does.
About Nicole Junkermann
Nicole Junkermann is an international investor focused on technology, artificial intelligence and life sciences. She is the founder of NJF Holdings, leading its venture arm NJF Capital, which backs early-stage companies in deep tech, healthcare and data-driven systems, and Gameday by NJF Holdings, focused on technology-led transformation in sport and media.